Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus HIPPURAN I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus HIPPURAN I 131.
CIS-MDP vs HIPPURAN I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical